| Primary |
| Product Used For Unknown Indication |
52.2% |
| Pneumonia |
13.0% |
| Immunosuppression |
6.5% |
| Prophylaxis |
6.5% |
| Antifungal Prophylaxis |
4.3% |
| Pneumocystis Jiroveci Infection |
4.3% |
| Pneumocystis Jiroveci Pneumonia |
4.3% |
| Acanthamoeba Keratitis |
2.2% |
| Bone Marrow Transplant |
2.2% |
| Off Label Use |
2.2% |
| Rheumatoid Arthritis |
2.2% |
|
| Bronchospasm |
7.1% |
| Drug Ineffective |
7.1% |
| Drug Interaction |
7.1% |
| Hypoaesthesia Oral |
7.1% |
| Lipase Increased |
7.1% |
| Obliterative Bronchiolitis |
7.1% |
| Pancreatitis |
7.1% |
| Renal Failure Acute |
7.1% |
| Respiratory Failure |
7.1% |
| Rheumatoid Arthritis |
7.1% |
| Salivary Hypersecretion |
7.1% |
| Unresponsive To Stimuli |
7.1% |
| Use Of Accessory Respiratory Muscles |
7.1% |
| Wheezing |
7.1% |
|
| Secondary |
| Product Used For Unknown Indication |
15.3% |
| Prophylaxis |
10.9% |
| Pneumocystis Jiroveci Pneumonia |
8.9% |
| Hiv Infection |
8.4% |
| Acquired Immunodeficiency Syndrome |
5.0% |
| Infection Prophylaxis |
4.5% |
| Lung Disorder |
4.5% |
| Antibiotic Prophylaxis |
4.0% |
| Clostridium Test Positive |
4.0% |
| Graft Versus Host Disease |
4.0% |
| Rheumatoid Arthritis |
4.0% |
| Antifungal Prophylaxis |
3.5% |
| Drug Use For Unknown Indication |
3.5% |
| Immunosuppression |
3.5% |
| Aspergillus Infection |
3.0% |
| Medulloblastoma |
3.0% |
| Pneumonia |
3.0% |
| Glioblastoma Multiforme |
2.5% |
| Multiple Myeloma |
2.5% |
| Opportunistic Infection |
2.5% |
|
| Sepsis |
9.7% |
| Acute Febrile Neutrophilic Dermatosis |
6.5% |
| Hypothermia |
6.5% |
| Lipase Increased |
6.5% |
| Mycobacterium Avium Complex Immune Restoration Disease |
6.5% |
| Nephrolithiasis |
6.5% |
| Pneumocystis Jiroveci Pneumonia |
6.5% |
| Subcutaneous Nodule |
6.5% |
| Torsade De Pointes |
6.5% |
| Urinary Tract Infection Enterococcal |
6.5% |
| Abdominal Pain Upper |
3.2% |
| Altered State Of Consciousness |
3.2% |
| Ascites |
3.2% |
| Cytomegalovirus Infection |
3.2% |
| Deafness Neurosensory |
3.2% |
| Dermatitis |
3.2% |
| Drug Ineffective |
3.2% |
| Drug Interaction |
3.2% |
| Haemolytic Anaemia |
3.2% |
| Hepatitis |
3.2% |
|
| Concomitant |
| Hiv Infection |
20.9% |
| Product Used For Unknown Indication |
16.4% |
| Drug Use For Unknown Indication |
10.9% |
| Prophylaxis |
10.2% |
| Infection Prophylaxis |
8.0% |
| Antifungal Prophylaxis |
4.7% |
| Bone Marrow Conditioning Regimen |
3.7% |
| Acute Lymphocytic Leukaemia |
3.5% |
| Prophylaxis Against Graft Versus Host Disease |
3.2% |
| Premedication |
2.7% |
| Pneumonia |
2.4% |
| Medulloblastoma |
1.9% |
| Multiple Myeloma |
1.7% |
| Hypertension |
1.5% |
| Acquired Immunodeficiency Syndrome |
1.5% |
| Aplastic Anaemia |
1.5% |
| Mycobacterium Avium Complex Infection |
1.5% |
| Antibiotic Prophylaxis |
1.4% |
| Prophylaxis Of Nausea And Vomiting |
1.2% |
| Prophylaxis Against Gastrointestinal Ulcer |
1.1% |
|
| Vomiting |
15.0% |
| Weight Decreased |
9.5% |
| Pyrexia |
7.3% |
| Sepsis |
6.6% |
| Thrombocytopenia |
6.2% |
| Graft Versus Host Disease In Skin |
5.5% |
| White Blood Cell Count Decreased |
5.1% |
| Multi-organ Failure |
4.4% |
| Respiratory Failure |
4.0% |
| Venoocclusive Disease |
4.0% |
| Pulmonary Embolism |
3.6% |
| Rash |
3.6% |
| Septic Shock |
3.6% |
| Trichosporon Infection |
3.6% |
| Liver Disorder |
3.3% |
| Subdural Haematoma |
3.3% |
| Cytomegalovirus Chorioretinitis |
2.9% |
| Immune Reconstitution Syndrome |
2.9% |
| Staphylococcal Infection |
2.9% |
| Off Label Use |
2.6% |
|
| Interacting |
| Drug Use For Unknown Indication |
100.0% |
|
| Electrocardiogram Qt Prolonged |
100.0% |
|
